2024/04/17 by Marco Bonilla, Orhan Efe, Haresh Selvaskandan +2 · 1 voice · 2 citations
Medicine · #Autoimmune Bullous Skin Diseases #Chronic Kidney Disease and Diabetes #Renal Diseases and Glomerulopathies
paper · pdf · doi:10.1016/j.xkme.2024.100826
openalex publication_date 2024/04/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
Focal segmental glomerulosclerosis (FSGS) defines a distinct histological pattern observed in kidney tissue, that is linked to several distinct underlying causes, all converging on the common factor of podocyte injury. It presents a considerable challenge in terms of classification due to its varied underlying causes and the limited correlation between histopathology and clinical outcomes. Critically, precise nomenclature is key to describe and delineate the pathogenesis, subsequently guiding the selection of suitable and precision therapies. A proposed pathomechanism-based approach has been suggested for FSGS classification. This approach differentiates between primary, secondary, genetic, and undetermined causes, aiming to provide clarity. Genetic FSGS from monogenic mutations can emerge during childhood or adulthood, and it is advisable to conduct genetic testing in cases where there is a family history of chronic kidney disease, nephrotic syndrome, or resistance to treatment. Genome-wide association studies have identified several genetic risk variants, such as in apolipoprotein L1 ( APOL1) , which play a role in the development of FSGS. Currently, no specific treatments have been approved to treat genetic FSGS; however, interventions targeting underlying cofactor deficiencies have shown potential in some cases. Furthermore, encouraging results have emerged from a phase 2 trial investigating inaxaplin, a novel small molecule APOL1 channel inhibitor, in APOL1 -associated FSGS.